Headlines about Aeglea Bio Therapeutics (NASDAQ:AGLE) have been trending positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aeglea Bio Therapeutics earned a news sentiment score of 0.29 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.0322447352246 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media headlines that may have effected Accern’s analysis:
- Aeglea Bio Therapeutics Inc (AGLE) Given Average Recommendation of “Buy” by Brokerages (americanbankingnews.com)
- Why Investors remained confident on: Grupo Financiero Galicia SA (NASDAQ:GGAL), International Seaways, Inc … (journalfinance.net)
- Average True Range (ATR 14) in the Limelight: Alio Gold Inc. (NYSE:ALO), Aeglea BioTherapeutics, Inc. (NASDAQ … (stocksnewspoint.com)
- Is Aeglea BioTherapeutics, Inc. (NasdaqGM:AGLE) Providing the Returns Investors Are Looking For? (parkcitycaller.com)
- Aeglea Bio Therapeutics (AGLE) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com)
A number of equities research analysts recently issued reports on the stock. ValuEngine upgraded shares of Aeglea Bio Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. BMO Capital Markets restated an “outperform” rating and issued a $18.00 target price on shares of Aeglea Bio Therapeutics in a report on Wednesday, March 14th. Needham & Company LLC boosted their target price on shares of Aeglea Bio Therapeutics from $8.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, March 14th. Evercore ISI assumed coverage on shares of Aeglea Bio Therapeutics in a report on Tuesday, April 24th. They issued an “outperform” rating and a $37.00 target price for the company. Finally, Zacks Investment Research upgraded shares of Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a report on Tuesday. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Aeglea Bio Therapeutics presently has a consensus rating of “Buy” and an average price target of $21.75.
Aeglea Bio Therapeutics traded down $0.11, reaching $10.57, during trading on Friday, MarketBeat reports. The company had a trading volume of 116,104 shares, compared to its average volume of 321,323. Aeglea Bio Therapeutics has a 12-month low of $2.81 and a 12-month high of $11.35. The company has a market cap of $233.45 million, a price-to-earnings ratio of -5.87 and a beta of -0.08.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). Aeglea Bio Therapeutics had a negative net margin of 507.82% and a negative return on equity of 54.83%. The company had revenue of $1.51 million during the quarter. analysts anticipate that Aeglea Bio Therapeutics will post -1.67 EPS for the current fiscal year.
In other Aeglea Bio Therapeutics news, major shareholder Bioventures Ltd Novartis sold 73,955 shares of the business’s stock in a transaction that occurred on Thursday, May 10th. The shares were sold at an average price of $10.12, for a total transaction of $748,424.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 27.00% of the stock is owned by insiders.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.